FDA Advisory Committee Supports Moderna mRNA Flu Vaccine Review

An FDA advisory committee has signaled its support for the review of Moderna’s mRNA-based influenza vaccine candidate. This move represents a critical milestone in expanding mRNA technology into the seasonal respiratory market, which has traditionally relied on egg-based or cell-based manufacturing processes. The potential approval of such a vaccine could disrupt the established pharmaceutical landscape for seasonal flu prevention by offering faster manufacturing timelines and potentially higher efficacy.